GSK plc
$160.85B- Market cap
- $104.74B
- Debt
- +$44.87B
- Cash
- −$3.40B
Capital structure 70% equity / 30% debt · EV / Revenue 3.64x · EV / EBITDA 18.90x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $104.74B · View financials
Snapshot Sep 8, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: GSK stock price vs SVC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SVC's multiple
Needs SVC P/E.
Implied fair value · at GSK's multiple
Needs Annual EPS is negative.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · SVC FY 2025 (ended Dec 31, 2025).
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 70% equity / 30% debt · EV / Revenue 3.64x · EV / EBITDA 18.90x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
SERVICE PROPERTIES TRUST · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
8.52x
Net debt / EBITDA
Leverage against operating earnings
6.59x
27.51x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$346.81M
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
HOST HOTELS & RESORTS, INC.
GSK vs HST
Sunstone Hotel Investors, Inc.
GSK vs SHO
Global Net Lease, Inc.
GSK vs GNL
REALTY INCOME CORP
GSK vs O
AGREE REALTY CORP
GSK vs ADC
KIMCO REALTY CORP
GSK vs KIM
$5.50B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.